The original disclosure in Japanese was released on January 30, 2019 at 15:00 (GMT+8)

To whom it may concern:

January 30, 2019CompanyTakara Bio Inc.

Headquarters

Nojihigashi 7-4-38, Kusatsu, Shiga 525-0058, Japan

Representative

Koichi Nakao, President & CEOContact

Shuichiro Matsuzaki, Executive Vice President

Telephone(+81)77-565-6970

Websitehttp://www.takara-bio.com/(First Section of the TSE, code: 4974)

Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
Kusatsu/Shiga, Japan-January 30, 2019 – Takara Bio Inc. (Takara Bio), today announced that a resolution has been
made at the meeting of the Board of Directors, to revise the consolidated financial forecast for the fiscal year

ending March 31, 2019 (April 1, 2018 – March 31, 2019) that was announced on November 6, 2018 and thedividend forecast that was announced on May 11, 2018, as follows based on a review of current trends in resultsof operations.
1. Revision to Financial Forecast(1) Revision to the Consolidated Forecast for the fiscal year ending March 31, 2019(April 1, 2018 – March 31, 2019)
Net sales

Operating income

Ordinary incomeNet income
attributable toowners of parent

Net income pershare

Million yen

Million yen

Million yen

Million yen

35,800

5,000

5,200

3,100

25.74

35,800

5,200

5,400

3,150

26.16

Amount of Change (B-A)

－200

200

50－

Percentage of change (%)(Reference) Results forthe previous fiscal year
ended March 31, 2018

－

4.0

3.8

1.6－

32,312

3,555

3,861

2,335

19.39

Previous forecast (A)Revised forecast (B)Yen(2) Reason of the Revision
Takara Bio expects that while the net sales in mushroom due to its business transfer and scientificinstruments will fall short of the plan, the solid sales in core research reagents and contracted service
cast that the shortfall can be absorbed. Accordingly, the overall net sales has been unchanged fromprevious forecast.
In terms of selling, general and administrative (SG&A) expenses, it is expected to fall below theplan in striving to reduce overall.
As a result, because operating income, ordinary income and net income attributable to owners of parent
are expected to be higher than the previous forecast, consolidated financial forecast for the year ending March
31, 2019 announced on November 6, 2018 has been upwardly revised.

12. Revision to Dividend Forecast(1) Details of Revised Dividend Forecast
Dividend per share (Yen)Record datend

End of 2 quarter

Previous forecast

End of fiscal year

Total

6.00

6.00

7.00

7.00

4.50

4.50

(Announced on May 11, 2018)
Revised forecast
Actual amount for the current fiscal year
Actual amount for the previous fiscalyear (fiscal year ended March 31, 2018)

0.00
0.00

(2) Reason of the Revision
Considering the management performance and financial statement comprehensively, Takara Bio
recognizes a basic policy aimed for profit contribution, positioning an important business
management issue to distribute profits to shareholders as well as enhancing the inter nal reserves tostrengthen the research development activities in Bioindustry and Gene Therapy businesses.
Specifically, the dividends of surplus will be paid at around 20% of estimated profit calculated
without considering extraordinary income or loss in the consolidated financial statements.
Takara Bio decided to upwardly revise the forecasted year-end dividend for fiscal 2019 by of ¥1.00
per share from ¥6.00 to ¥7.00 under the revision of financial forecast and the shareholder return policy
shown above.
As for the year-end dividend for fiscal 2019, it will be resolved at the 17 th Annual General Meetingof Shareholders held in June 2019.
(Note) The financial forecast shown above is based on information available as of the current date. Actual
financial results may differ from the forecast due to various reasons.

2